Brief: Mirati Therapeutics And Aadi Bioscience Partner To Evaluate Combination Of Adagrasib With NAB-Sirolimus In Patients With Advanced Non-Small Cell Lung Cancer And Other Solid Tumors With A Kras Mutation

Whitehawk Therapeutics

12/10/2022 13:04

Oct 12 (Reuters) - Aadi Bioscience Inc  AADI.O :
    * MIRATI THERAPEUTICS AND AADI BIOSCIENCE PARTNER TO
EVALUATE
COMBINATION OF ADAGRASIB WITH NAB-SIROLIMUS IN PATIENTS WITH
ADVANCED NON-SMALL CELL LUNG CANCER AND OTHER SOLID TUMORS WITH
A KRAS G12C  MUTATION
    * MIRATI THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, CO TO
BE
RESPONSIBLE FOR SPONSORING & OPERATING PHASE 1/2 STUDY
    * MIRATI THERAPEUTICS INC - CO JOINTLY WITH AADI, WILL
OVERSEE AND
SHARE COST OF STUDY

Source text for Eikon:  ID:nPn4fFlMna 
Further company coverage:  AADI.O 
 ((Reuters.Briefs@thomsonreuters.com;))